CASI Pharmaceuticals Total Assets 2011-2026 | CASI

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets CASI Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
138 M	128 M	103 M	113 M	45.1 M	27.7 M	5.83 M	11.3 M	15.5 M	8.98 M	3.24 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
138 M	3.24 M	54.5 M

Quarterly Total Assets CASI Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	128 M	119 M	130 M	138 M	136 M	145 M	148 M	128 M	128 M	128 M	128 M	103 M	103 M	103 M	103 M	113 M	113 M	113 M	113 M	45.1 M	45.1 M	45.1 M	45.1 M	27.7 M	27.7 M	27.7 M	27.7 M	5.83 M	5.83 M	5.83 M	5.83 M	11.3 M	11.3 M	11.3 M	11.3 M	15.5 M	15.5 M	15.5 M	15.5 M	8.98 M	8.98 M	8.98 M	8.98 M	3.24 M	3.24 M	3.24 M	3.24 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
148 M	3.24 M	59.3 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Adagene ADAG	89.3 M	$ 2.83	-2.75 %	$ 159 M	China
Biogen BIIB	28 B	$ 177.27	0.62 %	$ 25.8 B	USA
ANI Pharmaceuticals ANIP	1.28 B	$ 81.19	-0.98 %	$ 1.57 B	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Amgen AMGN	91.8 B	$ 339.82	-0.91 %	$ 182 B	USA
Aeglea BioTherapeutics AGLE	608 M	-	-	$ 1.01 B	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
BioNTech SE BNTX	22.5 B	$ 114.47	-1.97 %	$ 27.2 B	Germany
Burford Capital Limited BUR	3.11 B	$ 9.65	-0.16 %	$ 1.52 B	Britain
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Aytu BioScience AYTU	124 M	$ 2.56	-0.78 %	$ 16.1 M	USA
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.23	-0.92 %	$ 7.77 B	Australia
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Catalyst Biosciences CBIO	117 M	$ 10.0	-1.43 %	$ 658 M	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
Cerus Corporation CERS	201 M	$ 2.3	-1.08 %	$ 424 M	USA
Aptose Biosciences APTO	10.1 M	-	-45.71 %	$ 1.2 M	Canada
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Cellectis S.A. CLLS	384 M	$ 3.81	-4.51 %	$ 116 M	France
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Beam Therapeutics BEAM	1.1 B	$ 28.26	-3.52 %	$ 2.33 B	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Ascendis Pharma A/S ASND	1.18 B	$ 223.79	-0.07 %	$ 5 B	Danmark
Athira Pharma ATHA	58.8 M	-	-	$ 269 M	USA
Atreca BCEL	155 M	-	-11.76 %	$ 5.79 M	USA
Arrowhead Pharmaceuticals ARWR	1.39 B	$ 68.89	-0.33 %	$ 9.21 B	USA
Catalyst Pharmaceuticals CPRX	851 M	$ 24.53	-0.2 %	$ 2.91 B	USA
Cardiff Oncology CRDF	97.2 M	$ 1.68	3.75 %	$ 80.1 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Bellicum Pharmaceuticals BLCM	23.8 M	-	-9.72 %	$ 5.89 M	USA
Adaptimmune Therapeutics plc ADAP	283 M	-	-15.15 %	$ 60.3 M	Britain
Berkeley Lights BLI	226 M	-	-7.31 %	$ 87 M	USA
Can-Fite BioPharma Ltd. CANF	9.12 M	$ 4.03	-1.71 %	$ 8.77 B	Israel
Amneal Pharmaceuticals AMRX	3.5 B	$ 13.77	-2.45 %	$ 4.25 B	USA
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
Bellerophon Therapeutics BLPH	7.94 M	-	-74.18 %	$ 955 K	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA